Zobrazeno 1 - 10
of 96
pro vyhledávání: '"Ru Fang Yeh"'
Autor:
Johannes Bloehdorn, Andrejs Braun, Amaro Taylor-Weiner, Billy Michael Chelliah Jebaraj, Sandra Robrecht, Julia Krzykalla, Heng Pan, Adam Giza, Gulnara Akylzhanova, Karlheinz Holzmann, Annika Scheffold, Harvey E. Johnston, Ru-Fang Yeh, Tetyana Klymenko, Eugen Tausch, Barbara Eichhorst, Lars Bullinger, Kirsten Fischer, Martin Weisser, Tadeusz Robak, Christof Schneider, John Gribben, Lekh N. Dahal, Mathew J. Carter, Olivier Elemento, Dan A. Landau, Donna S. Neuberg, Mark S. Cragg, Axel Benner, Michael Hallek, Catherine J. Wu, Hartmut Döhner, Stephan Stilgenbauer, Daniel Mertens
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-18 (2021)
Chronic lymphocytic leukemia has been studied using multiple levels of omics data. Here, the authors use exome sequencing, SNP, protein and gene expression data to identify distinct biologic tumor subtypes with heterogeneous prognostic impact after c
Externí odkaz:
https://doaj.org/article/fc98052a777c445bb5de9e2a3b17c607
Autor:
Carlos Bais, Mallika Singh, Napoleone Ferrara, Priti Hegde, Jean-Philippe Stephan, Peng Yue, Ru-Fang Yeh, Hartmut Koeppen, Stefan J. Scherer, Daniel Chen, Sandra M. Swain, Sherry X. Yang, Jason H. Cheng, Anne C. Clermont, Rachel N.W. Tam, Benjamin Haley, Heidi Phillips, C. David James, Tomoko Ozawa, Zora Modrusan, Adrian Jubb, Alicia S. Chung, Ganesh Kolumam, Stefanie S. Jurinka, Joshua S. Kaminker, Xiumin Wu, Jenny Yao, Maike Schmidt, Guanglei Zhuang, Matthew J. Brauer
PDF file - 233K, Fig S4A. Validation and application of a compacted 22-gene VDV subset in human clinical samples. Fig S4B and C. Stratification of NO16966 patients by VEGF and CD31 expression levels.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3405c11a9339878f3e9e93b6cc47e414
https://doi.org/10.1158/1078-0432.22450911
https://doi.org/10.1158/1078-0432.22450911
Autor:
Carlos Bais, Mallika Singh, Napoleone Ferrara, Priti Hegde, Jean-Philippe Stephan, Peng Yue, Ru-Fang Yeh, Hartmut Koeppen, Stefan J. Scherer, Daniel Chen, Sandra M. Swain, Sherry X. Yang, Jason H. Cheng, Anne C. Clermont, Rachel N.W. Tam, Benjamin Haley, Heidi Phillips, C. David James, Tomoko Ozawa, Zora Modrusan, Adrian Jubb, Alicia S. Chung, Ganesh Kolumam, Stefanie S. Jurinka, Joshua S. Kaminker, Xiumin Wu, Jenny Yao, Maike Schmidt, Guanglei Zhuang, Matthew J. Brauer
PDF file - 154K, Fig S5. Most proxVDV genes are not obviously up-regulated by rVEGF in vitro.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2101a40bf0dd05131066a8c69bd8e6bb
https://doi.org/10.1158/1078-0432.22450908.v1
https://doi.org/10.1158/1078-0432.22450908.v1
Autor:
Johann S. de Bono, Howard A. Burris, Jennifer O. Lauchle, Joseph A. Ware, Hartmut Koeppen, Jill M. Spoerke, Jill O. Fredrickson, Ru-Fang Yeh, Doris Apt, Martijn P. Lolkema, Marjorie G. Zauderer, Tanguy Y. Seiwert, Lee M. Krug, Hedy L. Kindler, Johanna C. Bendell, Andrew J. Wagner, Saoirse O. Dolly
Purpose: This first-in-human phase I trial assessed the safety, tolerability, and preliminary antitumor activity of apitolisib (GDC-0980), a dual inhibitor of class I PI3K, and mTOR kinases.Experimental Design: Once-daily oral apitolisib was administ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4b3b50c179f79132800687cbfc8bbf93
https://doi.org/10.1158/1078-0432.c.6523982.v1
https://doi.org/10.1158/1078-0432.c.6523982.v1
Autor:
Carlos Bais, Mallika Singh, Napoleone Ferrara, Priti Hegde, Jean-Philippe Stephan, Peng Yue, Ru-Fang Yeh, Hartmut Koeppen, Stefan J. Scherer, Daniel Chen, Sandra M. Swain, Sherry X. Yang, Jason H. Cheng, Anne C. Clermont, Rachel N.W. Tam, Benjamin Haley, Heidi Phillips, C. David James, Tomoko Ozawa, Zora Modrusan, Adrian Jubb, Alicia S. Chung, Ganesh Kolumam, Stefanie S. Jurinka, Joshua S. Kaminker, Xiumin Wu, Jenny Yao, Maike Schmidt, Guanglei Zhuang, Matthew J. Brauer
PDF file - 83K, Fig S6. Effect of VDV gene expression and bevacizumab treatment in OS.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::21455c9a2b2718a4fb1d266c5777c1bf
https://doi.org/10.1158/1078-0432.22450905.v1
https://doi.org/10.1158/1078-0432.22450905.v1
Autor:
Carlos Bais, Mallika Singh, Napoleone Ferrara, Priti Hegde, Jean-Philippe Stephan, Peng Yue, Ru-Fang Yeh, Hartmut Koeppen, Stefan J. Scherer, Daniel Chen, Sandra M. Swain, Sherry X. Yang, Jason H. Cheng, Anne C. Clermont, Rachel N.W. Tam, Benjamin Haley, Heidi Phillips, C. David James, Tomoko Ozawa, Zora Modrusan, Adrian Jubb, Alicia S. Chung, Ganesh Kolumam, Stefanie S. Jurinka, Joshua S. Kaminker, Xiumin Wu, Jenny Yao, Maike Schmidt, Guanglei Zhuang, Matthew J. Brauer
PDF file - 113K, Fig S1. Kinetics of anti-VEGF effects on proliferation (ki67) and tumor burden in the RIP-TβAg model.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bad6ca4d0d237384ba43b86af47988b8
https://doi.org/10.1158/1078-0432.22450923.v1
https://doi.org/10.1158/1078-0432.22450923.v1
Autor:
Johann S. de Bono, Howard A. Burris, Jennifer O. Lauchle, Joseph A. Ware, Hartmut Koeppen, Jill M. Spoerke, Jill O. Fredrickson, Ru-Fang Yeh, Doris Apt, Martijn P. Lolkema, Marjorie G. Zauderer, Tanguy Y. Seiwert, Lee M. Krug, Hedy L. Kindler, Johanna C. Bendell, Andrew J. Wagner, Saoirse O. Dolly
Supplementary Table 1. Dose reductions and discontinuations in stage 2 Supplementary Table 2. Pharmacokinetic parameters of apitolisib Supplementary Table 3. Summary of radiological responses at the recommended phase 2 doses of 40mg and 30mg 28/28 da
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::00bd1755459ba4022d78329e6a9285dd
https://doi.org/10.1158/1078-0432.22458530.v1
https://doi.org/10.1158/1078-0432.22458530.v1
Autor:
Carlos Bais, Mallika Singh, Napoleone Ferrara, Priti Hegde, Jean-Philippe Stephan, Peng Yue, Ru-Fang Yeh, Hartmut Koeppen, Stefan J. Scherer, Daniel Chen, Sandra M. Swain, Sherry X. Yang, Jason H. Cheng, Anne C. Clermont, Rachel N.W. Tam, Benjamin Haley, Heidi Phillips, C. David James, Tomoko Ozawa, Zora Modrusan, Adrian Jubb, Alicia S. Chung, Ganesh Kolumam, Stefanie S. Jurinka, Joshua S. Kaminker, Xiumin Wu, Jenny Yao, Maike Schmidt, Guanglei Zhuang, Matthew J. Brauer
Purpose: The aim of this study was to identify conserved pharmacodynamic and potential predictive biomarkers of response to anti-VEGF therapy using gene expression profiling in preclinical tumor models and in patients.Experimental Design: Surrogate m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3bc72b77fad15d20bbc9887e354437ba
https://doi.org/10.1158/1078-0432.c.6522048
https://doi.org/10.1158/1078-0432.c.6522048
Autor:
Carlos Bais, Mallika Singh, Napoleone Ferrara, Priti Hegde, Jean-Philippe Stephan, Peng Yue, Ru-Fang Yeh, Hartmut Koeppen, Stefan J. Scherer, Daniel Chen, Sandra M. Swain, Sherry X. Yang, Jason H. Cheng, Anne C. Clermont, Rachel N.W. Tam, Benjamin Haley, Heidi Phillips, C. David James, Tomoko Ozawa, Zora Modrusan, Adrian Jubb, Alicia S. Chung, Ganesh Kolumam, Stefanie S. Jurinka, Joshua S. Kaminker, Xiumin Wu, Jenny Yao, Maike Schmidt, Guanglei Zhuang, Matthew J. Brauer
PDF file - 63K, Fig S3. Enrichment of VDV markers Tumor-Associated Endothelial Cells.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6d252f368587094fa15191021626c450
https://doi.org/10.1158/1078-0432.22450914.v1
https://doi.org/10.1158/1078-0432.22450914.v1
Autor:
Carlos Bais, Mallika Singh, Napoleone Ferrara, Priti Hegde, Jean-Philippe Stephan, Peng Yue, Ru-Fang Yeh, Hartmut Koeppen, Stefan J. Scherer, Daniel Chen, Sandra M. Swain, Sherry X. Yang, Jason H. Cheng, Anne C. Clermont, Rachel N.W. Tam, Benjamin Haley, Heidi Phillips, C. David James, Tomoko Ozawa, Zora Modrusan, Adrian Jubb, Alicia S. Chung, Ganesh Kolumam, Stefanie S. Jurinka, Joshua S. Kaminker, Xiumin Wu, Jenny Yao, Maike Schmidt, Guanglei Zhuang, Matthew J. Brauer
PDF file - 180K, Table S1. Genes in the VDV signature, ordered by anti-VEGF response in human IBC trial. Table S2. Gene Ontology terms over-represented in VDV signature. Table S3. Summary of tumors models tested.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c16e48fbc53c5122974e1b300e92cf33
https://doi.org/10.1158/1078-0432.22450902.v1
https://doi.org/10.1158/1078-0432.22450902.v1